Maxwell D. Cummings;Kristi A. Leonard;Heather Rae Hufnagel;Dana L. Johnson;Ehab Khalil;Richard W. Connors;Thomas P. Markotan;Anna C. Maroney;Tianbao Lu;Robert A. Galemmo;Jan L. Sechl;Richard Alexander
发明人:
Tianbao Lu,Richard Alexander,Richard W. Connors,Maxwell D. Cummings,Robert A. Galemmo,Heather Rae Hufnagel,Dana L. Johnson,Ehab Khalil,Kristi A. Leonard,Thomas P. Markotan,Anna C. Maroney,Jan L. Sechl
申请号:
US12187524
公开号:
US08173654B2
申请日:
2008.08.07
申请国别(地区):
US
年份:
2012
代理人:
摘要:
The invention is directed to triazolopyridazine compounds of Formula I:where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.